Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

This study has been completed.
Centocor, Inc.
Information provided by:
University of California, San Diego Identifier:
First received: December 30, 2005
Last updated: June 11, 2010
Last verified: November 2009
Results First Received: May 1, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Kawasaki Disease
Interventions: Drug: Infliximab (Remicade)
Biological: Intravenous immunoglobulin (IVIG)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
IVIG Arm (2 gr/kg) 2nd dose of IVIG (2gr/kg)
Infliximab (5mg/kg) Remicade (Infliximab Arm of 5mg/kg)

Participant Flow:   Overall Study
    IVIG Arm (2 gr/kg)     Infliximab (5mg/kg)  
STARTED     12     12  
COMPLETED     12     12  
NOT COMPLETED     0     0  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
IVIG Arm (2 gr/kg) 2nd dose of IVIG (2gr/kg)
Infliximab (5mg/kg) Remicade (Infliximab Arm of 5mg/kg)
Total Total of all reporting groups

Baseline Measures
    IVIG Arm (2 gr/kg)     Infliximab (5mg/kg)     Total  
Number of Participants  
[units: participants]
  12     12     24  
[units: participants]
<=18 years     12     12     24  
Between 18 and 65 years     0     0     0  
>=65 years     0     0     0  
[units: years]
Mean ± Standard Deviation
  1.833  ± .3     1.667  ± .3     1.75  ± .3  
[units: participants]
Female     3     4     7  
Male     9     8     17  
Region of Enrollment  
[units: participants]
United States     12     12     24  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration)   [ Time Frame: 2 weeks ]

2.  Primary:   Area Under the Curve of Infliximab Concentration Before Infliximab Infusion and Then 2 and 24 Hours, 1 Week (5 to 9 Days), 2 Weeks (12 to 16 Days), and 4 Weeks (26 to 30 Days) After Infliximab Infusion)   [ Time Frame: before infliximab infusion and then 2 and 24 hours, 1 week (5 to 9 days), 2 weeks (12 to 16 days), and 4 weeks (26 to 30 days) after infliximab infusion. ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Jane Burns, MD, Professor
Organization: University of California, San Diego
phone: 858-246-0155

No publications provided

Responsible Party: Jane C. Burns, University of California, San Diego Identifier: NCT00271570     History of Changes
Other Study ID Numbers: 041374, 2004-0548
Study First Received: December 30, 2005
Results First Received: May 1, 2009
Last Updated: June 11, 2010
Health Authority: United States: Food and Drug Administration